N/A N=150 Postoperative Pain Control Following Hysteroscopy
Postoperative Pain · Postoperative Nausea · Analgesia
Primary: Visual Analog Scale (VAS) — 2.49; 4.44; 1.23; 2.40 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Cryolipolysis for Jawline Contouring
Body Fat Disorder
Primary: Number of Participants With Unanticipated Adverse Device Effects (UADE) — 0 Participants with UADE reported
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
Phase 3 N=366 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Mantle-Cell Lymphoma
Primary: Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in) — 1; 0 Participants
Phase 3 N=450 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Carcinoma, Squamous Cell
Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243
Phase 2 N=145 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Arthritis, Rheumatoid
Primary: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 2; 3; 1 Participants
Phase 2 N=5 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant
Primary Immunodeficiency · PID
Primary: Safety: Death — 4 Participants
N/A N=46 Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy
Achilles Tendinopathy
Primary: Victorian Institute of Sports Assessment - Achilles (VISA-A) — 37.55; 43.82; 36.08; 46.92 score on a scale
Phase 3 N=186 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
Chronic Migraine · Episodic Migraine
Primary: Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs) — 88.4; 90.3; 4.5; 0.0 percentage…
Phase 2 N=109 Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer
HER2-positive Breast Cancer · Metastatic Breast Cancer
Primary: Progression Free Survival — 4.6 months
Phase 3 N=238 Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
Pruritus
Primary: Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS) — -2.86; -2.15 Scores on a scale — p=0.001
N/A N=321 The Experiences of Erotic and Sexual Risk of Transgender Men: Exploratory Research Design
Transgender Persons · Sexual Health
Primary: Experience of Erotic and Sexual Risk of Transgender Men(Demographic Data, Transgender Affirmation Questionnaire) — 269; 52; 166; 37 Participants
Phase 2 N=81 Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Bladder Cancer · Melanoma
Primary: Confirmed Objective Response in Bladder Cancer Participants to Nivolumab Monotherapy — 23 percentage of participants with PR/CR
Phase 3 N=64 Hyaluronic Acid in Overuse Knee Pain
Overuse Injury · Body Mass Index in Athletes
Primary: Efficacy of Hyaluronic Acid With Sorbitol (SYNOLIS VA) in Overuse Knee Syndrome Assessed With the Knee Injury and Osteoarthritis Outcome Score (KOOS) — 68; 78; 84; 88…
Phase 3 N=478 Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Heavy Menstrual Bleeding · Uterine Fibroids
Primary: Number of Participants With Adverse Events (AEs) — 203; 83; 124; 59 Participants